Related references
Note: Only part of the references are listed.KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Yuxiang Ma et al.
ONCOLOGIST (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
LBA20Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC
Y Cheng et al.
ANNALS OF ONCOLOGY (2019)
KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Y. Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
Kexun Zhou et al.
LUNG CANCER (2019)
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France
Christos Chouaid et al.
LUNG CANCER (2019)
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Weiting Liao et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
Xiaohan Hu et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
Amy P. Abernethy et al.
PLOS ONE (2017)
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis
Pengfei Zhang et al.
TUMORI JOURNAL (2017)
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis
Pengfei Zhang et al.
TUMORI JOURNAL (2017)
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Toshio Shimizu et al.
INVESTIGATIONAL NEW DRUGS (2016)
Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System
Vivien W. Chen et al.
CANCER (2014)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
